# NeoCARD: Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer Patients

Source: https://onco.cc/trials/nct06845319/  
OnCo record `nct06845319` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of carboplatin, paclitaxel / nab-paclitaxel and pembrolizumab in triple-negative breast cancer, run by Medical University of South Carolina, now recruiting.

## Summary

NeoCARD: Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer Patients is a phase 2, interventional study registered as NCT06845319 by Medical University of South Carolina, with a registry enrolment figure of 43 participants, started 2025-10-20 and due to reach its primary completion in 2027-10-20. Interventions recorded: Carboplatin; Paclitaxel; Pembrolizumab. Conditions listed: Triple Negative Breast Cancer. Triple-negative eligibility wording from the registry: "Histologically confirmed triple-negative breast cancer (TNBC) or hormone receptor-low invasive breast carcinoma, with clinical anatomic Stage II or Stage IIIA/B disease as defined by the AJCC 8th Edition Breast Cancer Stating System". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: NeoCARD
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT06845319
- Phase: 2
- Setting: NeoCARD: A Response-Adapted Phase II Study of Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer Patients With Cardiomyopathy or Elevated Risk of Cardiotoxicity
- Sponsor: Medical University of South Carolina
- Enrolled: 43

## Sources

- ClinicalTrials.gov NCT06845319: https://clinicaltrials.gov/study/NCT06845319

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06845319.json